Endovia Health Sciences, Inc. (SBEV) Form 424B3 — Aug 28, 2026
Endovia Health Sciences, Inc. (formerly Splash Beverage Group, now trading as EDVA on NYSE American) filed a 424B3 prospectus registering the resale of up to 5,000,000 shares of common stock by C/M Capital Master Fund, LP under their September 19, 2025 equity line of credit. The company receives no proceeds from C/M's resales but may elect to draw up to $30,782,793 in additional gross proceeds under the $35,000,000 ELOC. If all 5,000,000 registered shares are issued, common shares outstanding would rise from 6,412,521 to 11,412,521, an increase of roughly 78 percent.
Key figures
- Gross Proceeds
- 30782793
- Shares Offered
- 5000000
- Shares Outstanding
- 6412521
- Options shares
- 1621445
- Warrant shares
- 1875384
- Royalty human use
- 15%
- Reverse split ratio
- 1-for-4 (effective July 24, 2026)
- Prior eloc shares sold
- 4924459
- Royalty veterinary use
- 10%
- Oid notes principal usd
- 2200000
- Nyse compliance deadline
- January 29, 2027
- Eloc total commitment usd
- 35000000
- Fy2025 non cash items usd
- 14200000
- Series d stated value usd
- 5500000
- Vwap purchase floor price
- 3.4
- Fixed purchase floor price
- 3.6
- Potential dilution percent
- approximately 78%
- Prior eloc gross proceeds usd
- 4217207
- Trading halt price 2026 07 16
- 0.0936
- Cannepil licensor sales 2023 usd
- 4262155
- Cannepil licensor sales 2024 usd
- 894263
- Cannepil licensor sales 2025 usd
- 121497
- Post offering shares outstanding
- 11412521
- Max eloc shares at original floor
- 43750000
- Fy2025 net loss continuing ops usd
- 25200000
- Convertible notes underlying shares
- 3899658
- Last reported sale price 2026 08 19
- 0.41
- Options weighted avg exercise price
- 5.4
- Cannepil licensor sales 2026 ytd usd
- 98639
- Warrants weighted avg exercise price
- 41.2
- Commitment note outstanding balance usd
- 536961
- Convertible preferred underlying shares
- 10566267
- Estimated capital need next 12 months usd
- 2000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.